Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;33(2):428-33.
doi: 10.2337/dc09-1499.

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

Daniel J Drucker  1 , Steven I Sherman, Fred S Gorelick, Richard M Bergenstal, Robert S Sherwin, John B Buse
Affiliations

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

Daniel J Drucker et al. Diabetes Care. 2010 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relative comparison of properties exhibited by different classes of agents approved for the treatment of type 2 diabetes. CVD, cardiovascular disease; TG, triglycerides; CHF, congestive heart failure. A1C reduction depends on starting A1C.
Figure 2
Figure 2
Comparison of features associated with exenatide twice daily versus the properties of the emerging class of long-acting GLP-1R agonists that achieve more prolonged and sustained GLP-1R activation. CVD, cardiovascular disease.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008; 31: 81– 86 - PubMed
    1. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009; 122: 443– 453 - PubMed
    1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman BAmerican Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193– 203 - PMC - PubMed
    1. Bergenstal RM, Bailey CJ, Kendall DM. Therapeutic decision-making in type 2 diabetes: assessing the relative risks and benefits of glucose lowering medications. Am J Med In press - PubMed
    1. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter LDURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240– 1250 - PubMed

Publication types